MDGL insider buying – Madrigal Pharmaceuticals, Inc.
14 insider purchases since 2016 worth $141.0M by 9 different insiders. Last 12 months: 0 purchases, $0. Most recent filing: 2025-08-20.
Large company Public float $5.6B (latest 10-K, SEC).
Same time range as the chart above - each mark sits under the week of the trade. Circles = purchases (height = price paid, size = amount), red triangles = open-market sales of $50k+. Prices as reported, not adjusted for later stock splits. 6 older purchases (before the 5-year window) are listed in the table below.
Purchases are open-market buys (SEC Form 4, code "P") - insiders paying with their own money. Sales are open-market sales (code "S") of $50,000 or more; many sales are pre-planned (Rule 10b5-1) or made for taxes and diversification. Each row links to the original filing.
Bought, sold, still holding?
| Insider | Bought | First / last buy | Sold since 2016 | Holds now* | Status |
|---|---|---|---|---|---|
| BAKER FELIX Director | $40.8M 2× · 176,117 sh | 2023-11-13 2025-08-18 | – | 1,843,469 shares as of 2025-08-20 | Holds - never sold |
| Baker Bros. Advisors (GP) LLC Director | $36.9M 1× · 97,065 sh | 2025-08-18 2025-08-18 | – | 1,947,968 shares as of 2025-08-20 | Holds - never sold |
| BAKER BROS. ADVISORS LP Director | $22.5M 1× · 101,792 sh | 2023-12-13 2023-12-13 | – | 1,720,287 shares as of 2023-12-14 | Holds - never sold |
| BAKER JULIAN Director | $19.9M 2× · 113,737 sh | 2023-11-14 2023-11-21 | – | 1,612,339 shares as of 2023-11-21 | Holds - never sold |
| Baker Brothers Life Sciences LP Director | $11.9M 1× · 67,079 sh | 2023-11-17 2023-11-17 | – | 1,948,876 shares as of 2026-06-18 | Holds - never sold |
| 667, L.P. Director | $7.5M 1× · 34,578 sh | 2023-12-12 2023-12-12 | – | 1,669,016 shares as of 2023-12-14 | Holds - never sold |
| FRIEDMAN PAUL A CEO | $967,520 2× · 8,000 sh | 2018-11-19 2018-11-20 | 10× · $147.4M last 2026-01-09 | 855,884 shares as of 2026-01-13 | Sold part |
| CRAVES FRED B Director | $249,387 1× · 2,000 sh | 2018-11-19 2018-11-19 | 7× · $220.8M last 2025-03-12 | 364,275 shares as of 2025-03-14 | Sold part |
| Levy Richard S Director | $145,803 3× · 9,100 sh | 2017-08-21 2017-08-23 | 6× · $20.0M last 2026-05-22 | 22,469 shares as of 2026-06-18 | Sold part |
* Shares held after the insider's most recent SEC filing for this company (all share classes, direct and indirect). If an insider stops filing, later changes are not known.
Insider buying and selling by year
| Year | Purchases | Bought | Buyers | Sales | Sold |
|---|---|---|---|---|---|
| 2026 | 0 | – | – | 21 | $40.2M |
| 2025 | 2 | $61.9M | 2 | 33 | $179.8M |
| 2024 | 0 | – | – | 17 | $75.9M |
| 2023 | 6 | $77.8M | 5 | 7 | $16.8M |
| 2022 | 0 | – | – | 2 | $10.1M |
| 2020 | 0 | – | – | 3 | $6.9M |
| 2019 | 0 | – | – | 1 | $126.6M |
| 2018 | 3 | $1.2M | 2 | 4 | $183.3M |
| 2017 | 3 | $145,803 | 1 | – | – |
Insider purchases
| Filed | Insider | Role | Shares | Avg price | Value | Holdings | Filing |
|---|---|---|---|---|---|---|---|
| 2025-08-20 | Baker Bros. Advisors (GP) LLC | Director | 97,065 | $380.58 | $36.9M | +5.2% | SEC |
| 2025-08-20 | BAKER FELIX | Director | 68,618 | $364.04 | $25.0M | +3.8% | SEC |
| 2023-12-14 | BAKER BROS. ADVISORS LP | Director | 101,792 | $221.20 | $22.5M | +6.0% | SEC |
| 2023-12-14 | 667, L.P. | Director | 34,578 | $218.31 | $7.5M | +2.1% | SEC |
| 2023-11-21 | BAKER JULIAN | Director | 64,350 | $188.47 | $12.1M | +4.0% | SEC |
| 2023-11-21 | Baker Brothers Life Sciences LP | Director | 67,079 | $178.11 | $11.9M | +4.4% | SEC |
| 2023-11-15 | BAKER JULIAN | Director | 49,387 | $158.13 | $7.8M | +3.3% | SEC |
| 2023-11-15 | BAKER FELIX | Director | 107,499 | $146.99 | $15.8M | +7.7% | SEC |
| 2018-11-23 | FRIEDMAN PAUL A | CEO | 4,000 | $117.88 | $471,520 | +2.5% | SEC |
| 2018-11-19 | FRIEDMAN PAUL A | CEO | 4,000 | $124.00 | $496,000 | +2.6% | SEC |
| 2018-11-19 | CRAVES FRED B | Director | 2,000 | $124.69 | $249,387 | +0.7% | SEC |
| 2017-08-24 | Levy Richard S | Director | 2,000 | $16.12 | $32,236 | +28.2% | SEC |
| 2017-08-23 | Levy Richard S | Director | 3,550 | $16.12 | $57,209 | +100.0% | SEC |
| 2017-08-22 | Levy Richard S | Director | 3,550 | $15.88 | $56,358 | SEC |
Insider sales
| Filed | Insider | Role | Shares | Avg price | Value | Type | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Sibold William John | CEO | 11,583 | $538.65 | $6.2M | Pre-planned (10b5-1) | SEC |
| 2026-08-20 | Kelley Shannon T | Officer | 664 | $514.97 | $341,940 | Sale | SEC |
| 2026-07-20 | Sibold William John | CEO | 2,500 | $547.30 | $1.4M | Sale | SEC |
| 2026-06-01 | Soergel David | Officer | 1,042 | $495.74 | $516,561 | Pre-planned (10b5-1) | SEC |
| 2026-05-22 | Levy Richard S | Director | 5,682 | $515.44 | $2.9M | Pre-planned (10b5-1) | SEC |
| 2026-05-18 | Soergel David | Officer | 844 | $515.90 | $435,420 | Sale | SEC |
| 2026-03-06 | Taub Rebecca | Director | 491 | $431.94 | $212,083 | Sale | SEC |
| 2026-03-06 | Sibold William John | CEO | 1,663 | $431.94 | $718,316 | Sale | SEC |
| 2026-03-06 | Kelley Shannon T | Officer | 360 | $431.94 | $155,498 | Sale | SEC |
| 2026-03-06 | Huntsman Carole | Officer | 419 | $431.94 | $180,983 | Sale | SEC |
| 2026-03-06 | Dier Mardi | CFO | 1,982 | $430.87 | $853,993 | Pre-planned (10b5-1) | SEC |
| 2026-03-02 | Dier Mardi | CFO | 1,183 | $427.21 | $505,389 | Sale | SEC |
| 2026-01-26 | Taub Rebecca | Director | 647 | $492.42 | $318,596 | Sale | SEC |
| 2026-01-26 | Sibold William John | CEO | 1,577 | $492.42 | $776,546 | Sale | SEC |
| 2026-01-26 | Huntsman Carole | Officer | 910 | $493.78 | $449,339 | Pre-planned (10b5-1) | SEC |
Showing the latest 15 of 88 sales of $50,000+ since 2016.
Compiled automatically from public SEC filings. Not investment advice. Get every new insider purchase in the daily report.
Get every new insider purchase the day it's filed
Daily report with all SEC insider buys, cluster buys, company events and the crypto money-flow radar.
Get started free